High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M J GlantzM J Egorin

Abstract

Standard treatments for neoplastic meningitis are only modestly effective and are associated with significant morbidity. Isolated reports suggest that concurrent systemic and intrathecal (i.t.) therapy may be more effective than i.t. therapy alone. We present our experience, which includes CSF and serum pharmacokinetic data, on the use of high-dose (HD) intravenous (i.v.) methotrexate (MTX) as the sole treatment for neoplastic meningitis. Sixteen patients with solid-tumor neoplastic meningitis received one to four courses (mean, 2.3 courses) of HD (8 g/m2 over 4 hours) i.v. MTX and leucovorin rescue. Serum and CSF MTX concentrations were measured daily. Toxicity, response, and survival were retrospectively compared with a reference group of 15 patients treated with standard i.t. MTX during the same time interval. Peak methotrexate concentrations ranged from 3.7 to 55 micromol/L (mean, 17.1 micromol/L) in CSF and 178 to 1,700 micromol/L (mean, 779 micromol/L) in serum. Cytotoxic CSF and serum MTX concentrations were maintained much longer than with i.t. dosing. Toxicity was minimal. Cytologic clearing was seen in 81% of patients compared with 60% of patients treated intrathecally (P = .3). Median survival in the HD i.v. MTX grou...Continue Reading

Citations

Apr 28, 2005·Expert Review of Neurotherapeutics·Larry Recht, Surasak Phuphanich
Jun 21, 2007·Current Treatment Options in Neurology·Jan Drappatz, Tracy T Batchelor
Jun 30, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Alain P AlgaziJames L Rubenstein
Mar 30, 2010·Expert Opinion on Pharmacotherapy·Cagatay ArslanKadri Altundag
Jul 29, 2011·The Oncologist·Giuseppe LombardiVittorina Zagonel
Apr 13, 2011·Current Treatment Options in Neurology·Seema Nagpal, Lawrence Recht
Jun 28, 2012·Current Treatment Options in Neurology·Jordi BrunaRoser Velasco
Jan 29, 2013·Journal of Neuro-oncology·Priya KumthekarJeffrey J Raizer
Mar 26, 2013·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·P GavianiA Silvani
Apr 8, 2020·International Cancer Conference Journal·Yuki IkedaJunji Kato
Feb 6, 2002·Current Treatment Options in Neurology·Lauren E. Abrey
Apr 4, 2002·Clinical Pharmacokinetics·Tali Siegal, Ester Zylber-Katz
Nov 25, 2005·Journal of Neuro-oncology·Shearwood McClellandRobert R Goodman
Dec 14, 2005·Journal of Neuro-oncology·Andrew B LassmanJeffrey J Raizer
Mar 3, 2007·Journal of Neuro-oncology·B Gleissner, M Chamberlain
Dec 1, 2006·Neurosurgical Focus·Kaan GündüzBrian Patrick O'Neill
Dec 1, 2006·Neurosurgical Focus·Kristoph JahnkeEdward A Neuwelt
Oct 13, 2006·Current Treatment Options in Oncology·Lyndon Kim, Michael Glantz
Dec 22, 2004·Current Oncology Reports·Jeanine Grier, Tracy Batchelor
Feb 4, 2010·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Petra FeyerRolf Sauer
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc C Chamberlain
Nov 1, 2011·Journal of Gastrointestinal Cancer·Amardeep Singh AulakhBilal Piperdi
Jul 28, 2012·Current Treatment Options in Oncology·Seema NagpalHeather Wakelee
May 30, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy T Batchelor
Aug 15, 2014·Journal of Korean Medical Science·Jeanny KwonSung W Ha
Jun 28, 2014·Current Hematologic Malignancy Reports·Elizabeth H PhillipsKate Cwynarski
Aug 13, 2013·Current Treatment Options in Oncology·Lakshmi Nayak, Tracy T Batchelor
Aug 22, 2013·Blood·James L RubensteinPatrick Treseler
Dec 4, 2016·Hematology·Tracy T Batchelor
May 31, 2017·Cancer Control : Journal of the Moffitt Cancer Center·Sajeel ChowdharyMarc C Chamberlain
Oct 27, 2017·Oncotarget·Gautam NayarPeter E Fecci
Apr 3, 2018·The Journal of Veterinary Medical Science·Naofumi OgushiMinoru Shimoda

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.